DOI:
10.1055/s-00032260
Digestive Disease Interventions
LinksClose Window
References
El-Khoueiry AB, Sangro B, Yau T. et al.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Lancet 2017;
389 (10088): 2492-2502
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.